Latest Breaking News On - Hemispherix biopharma inc - Page 1 : comparemela.com

On February 23, the Food and Drug Administration (FDA) withdrew approval of Pepaxto (melphalan flufenamide), a drug that it had previously granted accelerated approval for treatment of.

Intercept pharms incDrug administrationHemispherix biopharma incNew drug applicationDrug omnibus report actNot withdraw accelerated approval mostMalignant hematologicalDraft guidanceDemonstrating substantial evidenceHuman drugBiological productsPeter marksFinal decisionWithdraw approvalProviding submissionsNon electronic format